Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 7/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16629905 | 0.95 | TOP1 (0.33) | TOP1NPC1CYP2A6GRM4 | |
| SCHEMBL16629654 | 0.88 | TOP1 (0.34) | TOP1NPC1CYP2A6AKT1KDM4E | |
| SCHEMBL16629651 | 0.85 | CYP1A2 (0.39) | TOP1NPC1CYP2A6AKT1KDM4E | |
| SCHEMBL16629730 | 0.83 | KDM4E (0.33) | TOP1KDM4ELMNAGAASMN1; SMN2 | |
| SCHEMBL16629701 | 0.81 | TOP1 (0.33) | TOP1NPC1CYP2A6KDM4ECYP1A2 | |
| SCHEMBL16629741 | 0.79 | KDM4E (0.31) | KDM4ELMNAGAASMN1; SMN2HSD17B10 | |
| SCHEMBL21335763 | 0.78 | MMP2 (0.33) | KDM4ELMNASMN1; SMN2 | |
| SCHEMBL16629916 | 0.78 | CYP1A2 (0.38) | TOP1NPC1CYP2A6KDM4ECYP1A2 | |
| SCHEMBL16629906 | 0.77 | NPC1 (0.36) | TOP1NPC1CYP2A6KDM4ECYP1A2 | |
| SCHEMBL24905024 | 0.77 | MCL1 (0.33) | KDM4ESMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407394-B2 | Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices | MERCK PATENT GMBH (DE) | 2019-09-10 | — | — | US | disclosed |
| US-20160214942-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214942-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| WO-2015049022-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214942-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | KCNQ1, KCNH1, KCNQ2 | TOP1 721/4885NPC1 3446/4885CYP2A6 771/4885 |
| US-10407394-B2 | Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices | KCNQ1, KCNH1, KCNQ2 | TOP1 721/4885NPC1 3446/4885CYP2A6 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.